Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 2014 , Vol 5, Issue 3
High Mobility Group Box 1 and Cancer
Mustafa Yıldırım2, Dinç Süren3, Özlem Demirpençe4, Vildan Kaya1
1Süleyman Demirel Üniversitesi Tıp Fakültesi Hastanesi, Radyasyon Onkolojisi Anabilim Dalı, Isparta, Türkiye
2Batman Bölge Devlet Hastanesi, Medikal Onkoloji Kliniği, Batman, Türkiye
3Antalya Eğitim Araştırma Hastanesi, Patoloji Kliniği, Antalya, Türkiye
4Batman Bölge Devlet Hastanesi, Biyokimya Kliniği, Batman, Türkiye
Aim: High mobility group box (HMGB) proteins are non-histone nuclear proteins which have many different functions. HMGB1 is the most important member of this family. It binds to the small groove of DNA nonspesifically and modifies the interaction of DNA with some of the transcription factors, including p53 and steroid hormone receptors. HMGB1 is secreted passively from necrotic cells and actively from inflammatory cells and binds to its most important receptor, RAGE (receptor for advanced glycation end products). HMGB1 plays a role in cell differantiation, cell migration, tumor metastasis and inflammation. There is increasing evidence on the role of HMGB1 in progression of cancer, angiogenesis, invasion and metastasis. There are studies suggesting that HMGB1 may have an important role in cancer development. Thus, HMGB1 and its receptor RAGE have become important therapy targets. Therefore we think that studies that show the role of HMGB1 in prediction of therapy and determining the prognosis are important since they will help determine the types of cancer to be targeted. Keywords : high mobility group box B1, cancer, apoptosis, angiogenesis, target therapies